With new guidelines on how to treat and manage muscle-invasive bladder cancer, Jeffrey Holzbeierlein, MD, FACS, professor of urology, director of urologic oncology, interim chair of the department of urology, University of Kansas Health System, provided insight into how the guidelines have changed the management of the disease at the 2018 Genitourinary Cancers Symposium.
With new guidelines on how to treat and manage muscle-invasive bladder cancer, Jeffrey Holzbeierlein, MD, FACS, professor of urology, director of urologic oncology, interim chair of the department of urology, University of Kansas Health System, provided insight into how the guidelines have changed the management of the disease at the 2018 Genitourinary Cancers Symposium.
According to Holzbeierlein, this was the American Urological Association’s first attempt at a true multidisciplinary guideline, and it was created with the American Society for Radiation Oncology, the American Society of Clinical Oncology, and Society of Urologic Oncology.
The methodology for ranking the strength of the studies in the guideline were as followed:
Based on those levels of evidence, the panel either made a strong recommendation, moderate recommendation, or a conditional recommendation.
Also in the guidelines are clinical principles and expert opinions, explained Holzbeierlein. A clinical principle is a statement about a component of clinical care that is very widely agreed upon by urologists or other clinicians for which they may or may not be evidence in the medical literature. An expert opinion is a statement achieved by consensus of the panel, that is based on members’ clinical training, experience, knowledge, and judgement for which there is no published evidence.
“Unfortunately, the prognosis of bladder cancer hasn’t really changed much over the last 30 years,” said Holzbeierlein. “The survival rates obviously vary by the treatment and by stage. We know that most recurrences occur within 2 to 3 years following cystectomy.”
During initial patient evaluation and counseling, the guidelines recommend that curative treatment options should be discussed before determining a plan of therapy that is based on both patient comorbidity and tumor characteristics. Patient evaluation should be completed using a multidisciplinary approach.
The panel felt very strongly that this should be a multidisciplinary approach, said Holzbeierlein. It is recommended that patients who have a new diagnosis of nonmetastatic muscle invasive bladder cancer should visit with a urologist, a radiation oncologist, and medical oncologist when available.
The guidelines provide a strong recommendation that surgically eligible patients with resectable nonmetastatic disease should be offered radical cystectomy with bilateral pelvic lymphadenectomy, combined with neoadjuvant chemotherapy.
According to Holzbeierlein, there is also a lot of evidence supporting multimodality therapy. While there may not be very strong studies suggesting head-to-head RCTs, the panel felt that the available evidence supported the recommendation of neoadjuvant chemotherapy followed by radical cystectomy.
The panel also recommends that patients who undergo neoadjuvant chemotherapy should proceed with radical cystectomy as soon as possible, usually within 4 to 8 weeks after completion of chemotherapy.
“On the patient advocate side, there’s a strong emphasis on making sure patients receive as much detailed counseling regarding the care and management of their urinary diversion prior to discharge from the hospital,” said Holzbeierlein.
For patients newly diagnosed with muscle-invasive bladder cancer who wish to retain their bladder, or for those who are not candidates for radical cystectomy, lateral preservation therapy should be offered to patients, said Holzbeierlein. The panel prefers an approach of transurethral resection of bladder tumor, systemic chemotherapy, and radiation therapy, followed by surveillance.
“A lot of work still needs to be done on surveillance and what is the optimal way to follow our patients after their different types of treatments,” concluded Holzbeierlein. “The data in that area is not very good at this point in time, so that’s an area of further research.”
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More